{"id":20262,"date":"2026-11-19T05:18:07","date_gmt":"2026-11-19T08:18:07","guid":{"rendered":"https:\/\/rtmedical.com.br\/tmp-en-1795076286789\/"},"modified":"2026-11-19T05:18:14","modified_gmt":"2026-11-19T08:18:14","slug":"lung-cancer-survival-ala-2026","status":"publish","type":"post","link":"https:\/\/rtmedical.com.br\/en\/lung-cancer-survival-ala-2026\/","title":{"rendered":"Lung Cancer Survival Reaches 31% in ALA 2026 Report"},"content":{"rendered":"<p>Five-year lung cancer survival in the United States has reached 31.0%, according to the American Lung Association&#8217;s ninth annual \u201cState of Lung Cancer\u201d report, released on November 17, 2026. The first report in the series, published in 2018, put that figure at 18.1%, so survival has risen by almost 13 percentage points. The report also finds that 24.4% of eligible people were screened with low-dose CT (LDCT) in 2024, up from 18.2% in last year&#8217;s edition, which relied on 2022 data.<\/p>\n<p>Two problems persist alongside the progress: 42.6% of cases are still found at a late stage, when five-year survival drops to 12.0%, and every indicator varies widely between states and across racial and ethnic groups.<\/p>\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" class=\"alignright lazyload\" data-src=\"https:\/\/rtmedical.com.br\/wp-content\/uploads\/2026\/11\/lung-cancer-us-states-ala-2026.png\" alt=\"Chart of US lung cancer indicators showing worst state, national average and best state for five-year survival, early-stage diagnosis and low-dose CT screening\" width=\"640\" src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" style=\"--smush-placeholder-width: 1200px; --smush-placeholder-aspect-ratio: 1200\/630;\"><figcaption>Five-year survival, early-stage diagnosis and screening of eligible adults in the US: worst state, national average and best state. Data: American Lung Association, State of Lung Cancer 2026.<\/figcaption><\/figure>\n<h2>Key numbers from State of Lung Cancer 2026<\/h2>\n<p>The ALA expects 229,410 new lung cancer diagnoses in the US this year. The association says the rate of new cases has improved 11% over five years, with a national incidence of 52.1 per 100,000 people. The extremes are far apart: Utah has the lowest incidence at 24.6 per 100,000 and Kentucky the highest at 83.9 per 100,000, more than three times Utah&#8217;s rate.<\/p>\n<p>Massachusetts leads on survival at 40.9%, while Alabama ranks last at 23.8%. Early diagnosis, meaning cases found before the cancer has spread, stands at 29.3% nationally, best in Rhode Island (38.0%) and worst in Hawaii (21.9%). Five-year survival in that group is 65.0%. The report also finds that 20.9% of patients received no treatment at all, from 13.4% in Rhode Island to 36.7% in Nevada.<\/p>\n<p>\u201cLung cancer is a devastating disease, but the positive trends detailed in our latest report offer hope,\u201d said Harold Wimmer, the ALA&#8217;s president and CEO, in the press release, adding that not all communities have benefited from this progress. Five-year survival is 30.8% among white patients, 26.1% among Black patients and 18.2% among Indigenous Peoples; Latino patients are at 30.8% and Asian and Pacific Islander patients at 35.4%.<\/p>\n<h2>Low-dose CT screening: slow, uneven progress<\/h2>\n<p>The ALA screening rate comes from the CDC&#8217;s 2024 Behavioral Risk Factor Surveillance System (BRFSS), a self-reported telephone survey. Eligibility follows the 2021 US Preventive Services Task Force (USPSTF) recommendation: age 50 to 80, a smoking history of at least 20 pack-years, and current smoking or quitting within the past 15 years. Medicare covers screening only up to age 77.<\/p>\n<p>The national figure of 24.4% accounts for a data-source error described by Burus and colleagues at the University of Kentucky in JAMA Internal Medicine, the same study we covered in our piece on <a href=\"https:\/\/rtmedical.com.br\/en\/ct-lung-screening-uptake-real-world-mortality\/\">rising screening uptake and real-world mortality<\/a>. That analysis of 26,104 eligible respondents found a 6-percentage-point increase since 2022, significant gains in 21 states, and no change among Hispanic, Asian or Black adults. At the state level, the ALA report puts Massachusetts at 38.7% of eligible adults screened and South Dakota at 13.5%.<\/p>\n<p>Even with a USPSTF recommendation in place since 2013, three of every four eligible people are still not being screened. Approaches that target this gap, including patient navigation, electronic health record prompts and culturally tailored outreach, are the subject of <a href=\"https:\/\/rtmedical.com.br\/en\/lung-screening-uptake-jacr-strategies\/\">three recent JACR studies<\/a> that show where the screening order gets stuck.<\/p>\n<h2>Why stage at diagnosis matters so much<\/h2>\n<p>In the ALA methodology, \u201cearly stage\u201d corresponds to localized disease in the National Cancer Institute&#8217;s SEER summary staging, equivalent to stage I, and \u201clate stage\u201d corresponds to distant disease, equivalent to stage IV. The survival gap between the two, 65.0% versus 12.0%, is the reason screening sits at the center of the debate: the ALA notes that annual low-dose CT can cut lung cancer deaths by up to 20% in high-risk populations.<\/p>\n<p>The indicators, however, cover different time windows: survival comes from patients diagnosed between 2016 and 2022 in North American Association of Central Cancer Registries (NAACCR) data, before much of the screening growth measured in 2024. The ALA itself credits the survival gains to a mix of factors, namely new treatments such as targeted therapy and immunotherapy, biomarker testing and screening, without separating the weight of each. In our reading, part of any survival gain in screened populations may also reflect lead time and overdiagnosis, effects that only mortality data can strip out.<\/p>\n<h2>What the US report means for Brazil<\/h2>\n<p>In Brazil, the National Cancer Institute (INCA) projects 35,380 new cases of trachea, bronchus and lung cancer per year for 2026\u20132028 (18,730 in men and 16,650 in women), making it the fourth most common cancer once non-melanoma skin cancer is excluded. The disease caused 31,237 deaths in 2023. A 2024 recommendation from the Brazilian Society of Thoracic Surgery, the Brazilian Thoracic Association and the Brazilian College of Radiology, published in the Jornal Brasileiro de Pneumologia, states that only 15% of Brazilian patients are diagnosed at an early stage.<\/p>\n<p>Brazil has no organized national LDCT screening program. INCA states that screening is not recommended for the general population and that, for heavy smokers aged 50 to 80, the decision to be scanned should be shared between patient and physician. The medical societies recommend the scan for current and former smokers aged 50 or older with more than 20 pack-years. In April 2026, INCA and the Rio de Janeiro municipal health department launched a two-year feasibility study with at least 397 participants, funded by AstraZeneca, as we noted in our <a href=\"https:\/\/rtmedical.com.br\/en\/ldct-lung-screening-wclc-2026\/\">WCLC 2026 coverage<\/a>.<\/p>\n<p>For radiology services, the US lesson is operational: the gaps between states suggest that active outreach, CT capacity and a <a href=\"https:\/\/rtmedical.com.br\/en\/sustainable-lung-nodule-follow-up\/\">nodule follow-up pathway that actually works<\/a> matter as much as the scan itself. Reader variability is part of the same picture: <a href=\"https:\/\/rtmedical.com.br\/en\/radiologist-variability-lung-ct\/\">radiologists differ widely in how they read lung CT<\/a>, and a population program amplifies any inconsistency.<\/p>\n<h2>Limitations and what to watch<\/h2>\n<p>The screening figure is self-reported and may overstate true uptake; the 2022 dataset had a coding error that forced researchers to restrict time comparisons to ages 50 to 79. Some states lack indicators: survival data were unavailable for eight of them, and Tennessee has no screening rate. Comparisons with Brazil also need care, because staging definitions and data sources differ. Finally, the ALA is a patient advocacy organization and uses the report to back a bill on access to clinical trials.<\/p>\n<p>Upcoming reports should show whether the 2024 jump in screening translates into more stage I diagnoses and lower mortality. In Brazil, results from the INCA study in Rio are expected to be the first public data on whether lung screening is feasible within the public health system (SUS).<\/p>\n<p><strong>Source:<\/strong> <a href=\"https:\/\/theimagingwire.com\/2026\/11\/18\/progress-is-being-made-in-the-fight-against-lung-cancer\/\" target=\"_blank\" rel=\"noopener\">The Imaging Wire \u2014 Progress Against Lung Cancer<\/a>; <a href=\"https:\/\/www.lung.org\/research\/state-of-lung-cancer\/key-findings\" target=\"_blank\" rel=\"noopener\">American Lung Association \u2014 State of Lung Cancer 2026: Key Findings<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ALA&#8217;s State of Lung Cancer 2026: US lung cancer survival hits 31% and LDCT screening 24.4%. See the state-by-state gaps and what they mean.<\/p>\n","protected":false},"author":5,"featured_media":20227,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"ngg_post_thumbnail":0,"_rt_cluster":"","fifu_image_url":"","fifu_image_alt":"","footnotes":""},"categories":[100],"tags":[],"class_list":["post-20262","post","type-post","status-publish","format-standard","has-post-thumbnail","category-radiology"],"aioseo_notices":[],"rt_seo":{"title":"","description":"ALA's State of Lung Cancer 2026: US lung cancer survival hits 31% and LDCT screening 24.4%. See the state-by-state gaps and what they mean.","canonical":"","og_image":"","robots":"index,follow","schema_type":"Article","include_in_llms":true,"llms_label":"US lung cancer: ALA State of Lung Cancer 2026 report","llms_summary":"American Lung Association report (Nov 2026): US five-year lung cancer survival at 31.0% (18.1% in 2018), low-dose CT screening at 24.4% of eligible adults (2024 BRFSS), 29.3% diagnosed early, 42.6% late-stage, wide state and racial gaps; Brazilian context with INCA data.","faq_items":[],"video":[],"gtin":"","mpn":"","brand":"","aggregate_rating":[]},"_links":{"self":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20262\/"}],"collection":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/"}],"about":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/types\/post\/"}],"author":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/users\/5\/"}],"replies":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/comments\/?post=20262"}],"version-history":[{"count":1,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20262\/revisions\/"}],"predecessor-version":[{"id":20264,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/posts\/20262\/revisions\/20264\/"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/20227\/"}],"wp:attachment":[{"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/media\/?parent=20262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/categories\/?post=20262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rtmedical.com.br\/en\/wp-json\/wp\/v2\/tags\/?post=20262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}